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Urinary exosomes are excreted from all nephron segments
and constitute a rich source of intracellular kidney injury
biomarkers. To study whether they contain transcription
factors, we collected urine from two acute kidney injury
models (cisplatin or ischemia-reperfusion), two podocyte
injury models (puromycin-treated rats or podocin-Vpr
transgenic mice) and from patients with focal segmental
glomerulosclerosis, acute kidney injury and matched
controls. Exosomes were isolated by differential
centrifugation and found to contain activating transcription
factor 3 (ATF3) and Wilms Tumor 1 (WT-1) proteins
detected by Western blot. These factors were found in
the concentrated exosomal fraction, but not in whole urine.
ATF3 was continuously present in urine exosomes of the
rat models following acute injury at times earlier than the
increase in serum creatinine. ATF3 was found in exosomes
isolated from patients with acute kidney injury but not from
patients with chronic kidney disease or controls. Urinary
WT-1 was present in animal models before significant
glomerular sclerosis and in 9/10 patients with focal
segmental glomerulosclerosis but not in 8 controls.
Our findings suggest that transcription factor ATF3 may
provide a novel renal tubular cell biomarker for acute kidney
injury while WT-1 may detect early podocyte injury.
Measurement of urinary exosomal transcription factors
may offer insight into cellular regulatory pathways.
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Much effort is being expended in discovering noninvasive
biomarkers for acute and chronic kidney injury.1,2 Several
promising biomarker candidates are being evaluated for
their effectiveness for early detection, disease classification,
predicting severity/outcome, and/or predicting response
to treatment.2–22 Urinary exosomes are a rich source of
biomarkers because they are released from every segment
of the nephron, including podocytes.23 Exosomes are right-
side-out vesicles that originate from endocytic vesicles that
fuse with multivesicular bodies (MVB). Invagination of the
MVB membrane can form internal vesicles within the MVB
that have a right-side-out orientation. When an MVB fuses
with the plasma membrane, the internal vesicles enter the
extracellular space as exosomes.24 Membrane proteins such
as transporters and ion channels are expected to be highly
enriched in exosomes;23,25 however, exosomes can also
contain cytosolic proteins.23,26 Transcription factors (TF)
are found in the cytosol as well as the nucleus and should
theoretically be present in exosomes. However, TFs have not
been detected in exosomes using proteomics discovery
techniques, perhaps because TFs are usually expressed at
such low levels inside of cells.
Transcription factors can be activated by developmental,
physiological, pathological, and therapeutic stimuli. Because
they orchestrate the mobilization of several genes, TFs often
play central roles in the initiation and development of many
kidney diseases. Therefore, measuring TFs might be more
informative than measuring downstream proteins. In micro-
array experiments, mRNA levels of some TFs were markedly
induced during the early phase of acute kidney injury
(AKI)27–32 TFs also play important roles in the development
of glomerulosclerosis and tubulointerstitial fibrosis.33,34
Changes in mRNA levels do not always correspond to
changes in protein levels for a given gene;29,35 therefore, if
candidate genes are identified by microarray experiments, the
genes are best evaluated at the protein level before entering a
biomarker development pipeline.1
Transcription factors are expressed at low levels inside
of cells and are difficult to detect outside of cells; indeed,
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transcription factor proteins have not been detected in urine.
The purpose of this study was to determine whether TFs can
be detected in urine by examining the exosomal fraction and
whether TFs can serve as novel urinary biomarkers for acute
and chronic renal injury. We chose two transcription factors
previously identified by microarray studies: activating
transcription factor 3 (ATF3) for AKI29,31,36 and Wilms’
Tumor 1 (WT-1) for focal segmental glomerulosclerosis
(FSGS).37 We examined temporal expression of ATF3 in
ischemia/reperfusion (I/R) and cisplatin animal models of
AKI and a small number of human samples. We evaluated the
temporal expression of WT-1, which is often used as a
molecular marker for podocytes,34,38 in urinary exosomes
from puromycin-induced FSGS in rats and doxycycline-
induced collapsing glomerulopathy (CG) in podocin/Vpr
transgenic mice, and FSGS patients. This novel discovery
strategy of using the unique properties of urinary exosomes
to sample the intracellular and/or exported compartment
may allow new insights to be gained about cellular regulatory
pathways without an invasive renal biopsy.
RESULTS
Temporal urinary excretion of exosomal ATF3 in animal
models of AKI
Induction of AKI in cisplatin and I/R models was confirmed
by increases in serum creatinine (SCr; Figure 1) and histo-
logical evidence of renal tubule damage (data not shown).14
Urinary exosomal ATF3 increased significantly as early as
0–2 h after 35 min of ischemia and reperfusion, then
remained elevated in the 2–8 h and the 8–24 h collection
periods (Figure 1a). Urinary ATF3 also increased 24 h after
cisplatin injection, peaked at day 2 after cisplatin injection,
decreased to a very low level at day 3, and reappeared at day 5
(Figure 1b). Urinary ATF3 was detected 2 days before the SCr
increase and tubular damage (Figures 1b and 2). The biphasic
pattern was confirmed in two independent experiments,
although ATF3 was detected weakly in some animals at day 3
after cisplatin injection (data not shown). In contrast, ATF3
was not detected in urine exosomes from either normal or
volume-depleted rats (Figure 1c), or puromycin-treated rats,
an animal model of FSGS (data not shown).
Renal expression of ATF3 after cisplatin-induced AKI
To determine whether the changes in urinary exosomal ATF3
content reflected histological changes and/or changing
content of ATF3 in kidneys, we examined renal ATF3 protein
expression by immunohistochemistry. ATF3 was not detected
by immunohistochemical examination in normal kidney but
was increased in the nuclei of tubule epithelial cells in the
outer stripe of the outer medulla from days 1–5 after cisplatin
(Figure 2). ATF3 staining increased significantly in normal-
appearing proximal tubular cells on day 1 (Figure 2b) and
peaked on day 2 when renal function and histology remained
normal (Figure 2c). On day 3, when tubular injury became
evident, ATF3 was still detected in nuclei of cells attached
to the tubule basement membrane, but faint staining could
be detected in the cytoplasm as well. (Figure 2d). As cells
detached from the basement membrane on day 5 after
cisplatin, positive staining was detected in nuclei of detached
cells, but there was also staining in cellular debris (Figure 2e).
The primary antipeptide antibody was incubated with the
immunogenic peptide, to confirm the absence of nonspecific
staining (Figure 2f). Urinary ATF3 paralleled the initial rise in
renal ATF3 expression, but preceded the increase in SCr and
histological changes, by 2 days (Figures 1 and 2).
Urinary exosomal ATF3 in patients with AKI
Spot urine samples were collected from two healthy
volunteers and four ICU patients with AKI, including urine
collections at two different time points during the course of
AKI in two patients (Table 1), and four patients with chronic
kidney disease (Supplementary Table 1). We isolated exo-
somes from these urine samples and examined the abun-
dance of ATF3 normalized by urine creatinine. Urinary
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Figure 1 | Time course of excretion of urinary exosomal ATF3 in ischemic and nephrotoxic AKI rat models. Urinary exosomal
ATF3 from individual rats analyzed by western blotting. (a) I/R-induced AKI rats after 35 min of bilateral ischemia and reperfusion,
(b) Cisplatin-induced AKI rats, (c) volume depleted rats. þ , ATF3 positive control.
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exosomal ATF3 increased in the early phase of AKI based
on the time course of SCr in ICU patients (Figure 3). In
one patient, urinary ATF3 was already increased when
SCr started to rise and decreased to undetectable level when
SCr reached very high values (Figure 3a, middle panel). This
is similar to the cisplatin-induced AKI animal (Figure 1b).
In another patient, increased urinary ATF3 returned to the
undetectable level during the recovery phase of AKI (Figure 3,
right panel). In contrast, urinary ATF3 was not increased
in chronic kidney disease patients (Supplementary Figure 1
and Supplementary Table 1).
Urinary excretion of exosomal WT-1 in two podocyte
injury animal models
We examined the time course of urinary exosomal WT-1
excretion relative to nephrosis, which was established
(Table 2) within 14 days in puromycin-treated rats (an
FSGS model) and within 28 days in doxycycline-treated
podocin/Vpr transgenic mice (a collapsing glomerulopathy
model39,40). Urinary exosomal WT-1 was not detected in
either normal rats or noninduced podocin/Vpr transgenic
mice (Figure 4a and b). WT-1 started to increase very early
(days 1 and 3) after puromycin injection, before albuminuria
was detectable, was significantly increased at 7 days, and
remained elevated at 14 days in puromycin aminonucleoside
(PAN)-treated rats (Figure 4a). In podocin/Vpr transgenic
mice, urinary WT-1 also was detected at 7 days and
continued to increase progressively for 28 days of doxycycline
administration (Figure 4b), corresponding to the increasing
level of albuminuria (Figure 4c). Urinary WT-1 was detected
earlier than detection of albuminuria in FSGS rats and as
early as albuminuria in CG mice; although WT-1 and
albumin were detectable at 7 days in these mice, albumin was
not statistically significant from control (Figure 4c).
Urinary exosomal WT-1 was detected before histological
abnormalities were observed (Figures 4 and 5). Normal
glomerular morphology (Figure 5a) was observed in over
75% of the glomeruli at 14 days after PAN. Only 25% of
glomeruli showed expansion of mesangial matrix (Figure 5b,
arrow 1) and very few glomeruli had typical sclerosis such as
podocytes detached from the glomerular capillary (Figure 5b,
arrow 2) and adhesions between the glomerulus and
Bowman’s capsule (Figure 5b, arrow 3). Histology observed
after 14 days of Vpr induction by doxycycline (data not
Normal Cis-day 1
Cis-day 2
Cis-day 5 Antipeptide control (Cis-day 3)
Cis-day 3
a b
c d
e f
Figure 2 | Time course of immunohistochemical staining of
ATF3 in rats with cisplatin-induced AKI. Immunostaining of
renal ATF3 in outer stripe of outer medulla (a) before and at
(b) day 1, (c) day 2, (d) day 3, and (e) day 5 after cisplatin
injection in rats. Negative control: (f) day 3 after cisplatin primary
antibody was incubated with the corresponding peptide
before immunostaining.
Table 1 | Characteristics of ICU patients with AKI
Patients
Age/
gender Primary diagnosis
APACHE II
score AKI
Serum
creatinine
(mg/100 ml)
Blood urea
nitrogen
(mg/100 ml)
Urine
output
(ml/day)
Furosemide
(mg)
Blood
culture SIRS Sepsis WBC
Temperature
(1C)
A1 51/M Pneumonia 24 Yes 3.8 68 1555 Yes Positive Yes Yes 11 36.7
A2 71/M Abdominal pain,
mesenteric ischemia
16 Yes 2.1 73 1961 No Negative Yes Yes 10.45 36.7
A3 26/M Epileptics
Time point-1 25 Yes 2.5 20 1520 No Negative No No 11.66 37.3
Time point-2 (6 days later) 25 Yes 7.1 120 1515 No Positive Yes Yes 9.7 39.4
A4 73/M UTI, hyponephrosis, urosepsis
Time point-1 11 Yes 3.5 110 765 Negative No No 6.72 36.7
Time point-2 (12 days later) 9 Recovered 1.2 31 3550 Negative No No 11.16 37.8
AKI-PTs ATF3
Scr (mg/100 ml)
N1 N2 PT1 PT2 PT3 PT4
0.6 0.5 3.1 2.1 2.5 7.1 3.5 1.2
Figure 3 | Urinary exosomal ATF3 in human subjects.
Comparison of ATF3 in spot urine samples from two healthy
volunteers and two AKI patients (left panel); urine samples at two
time points (rising and peak SCr) from a third AKI patient (middle
panel); and urine samples at two time points (high SCr and during
recovery) from a fourth AKI patient (right panel).
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shown) was indistinguishable from the contralateral normal
kidney harvested during uninephroctomy (Figure 5c). In
contrast, severe glomerular damage could be detected after
28 days of doxycycline induction. We saw increased mesan-
gial matrix in half of the glomeruli (Figure 5d, arrow 1),
protein casts in cortical tubules (Figure 5d, #), and glome-
rular crescents in Bowman’s capsule (Figure 5d, *).
Renal expression of WT-1 in podocin/Vpr mice with
collapsing glomerulopathy
We further examined the relationship between the amount of
urinary exosomal WT-1 and the staining of WT-1 in frozen
sections of mice treated with doxycycline. In untreated
control podocin/Vpr transgenic mice, WT-1-positive cells
were detected in the periphery of glomeruli but not in renal
tubular cells (Figure 6a and c). The number of WT-1-positive
cells decreased slightly at 14 days (Figure 6d) and decreased
more prominently at 28 days (Figure 6b and e) after
uninephrectomy and continuous doxycycline administration.
Therefore, increases in urinary exosomal WT-1 correspond to
decreases in WT-1 staining in glomeruli.
Urinary exosomal WT-1 in FSGS patients
We collected spot urine samples from healthy volunteers
and FSGS patients. We analyzed urinary exosomal WT-1 by
western blotting after normalization by urine creatinine.
Urinary WT-1 was not detected in any healthy volunteers,
but was detected in 9 of 10 patients with FSGS (Figure 7).
WT-1 was not detected in AKI patients (data not shown).
Table 2 | Serologic data of FSGS animal models
Puromycin-treated rats DOX-treated podocin/Vpr transgenic mice
Pre-iv 2 weeks post-iv Untreated 4 weeks post–DOX
Total protein (g/100 ml) 4.52±0.09 3.05±0.07* 5.24±0.29 3.83±0.23*
Albumin (g/100 ml) 7.24±0.15 5.15±0.18* 3.56±0.21 2.53±0.15*
Blood urea nitrogen (mg/100 ml) 11.3±0.99 14.8±0.55 15.1±1.23 63±1.41*
Creatinine (mg/100 ml) 0.4±0.04 0.4±0.05 0.10±0.03 0.36±0.05*
*Po0.05
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Pre-iv
Pre-iv
1 day-post iv 3 days-post iv
14 days-post iv
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7 days-post iv
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Figure 4 | Time course of excretion of urinary exosomal WT-1
analyzed by western blotting in animal models of podocyte
injury. (a) FSGS rats: urinary exosomal WT-1 after puromycin
aminonucleoside injection to rats. The number under each blot is
semiquantative proteinuria by Chemstrip. Blots are shown from
two separate experiments. (b) CG mice: time course of urinary
WT-1 in uninephrectomy and doxycyclin-induced CG in podocin/
Vpr transgenic mice. (c) Albuminuria measured by albumin
enzyme-linked immunosorbent assay from podocin/Vpr
transgenic mice in a parallel experiment. *Po0.05 by analysis
of variance.
Normal rat
Normal podocin/Vpr mouse
FSGS rat—day 14
CG mouse—28 day
3
2
1
3
3
1
a b
c d
Figure 5 | Histology of the kidney sections stained with
periodic acid-Schiff reagent in the cortex in animal models of
podocyte injury. Morphologic changes in glomeruli from rats (a)
before and (b) 14 days after PAN injection; from podocin/Vpr
transgenic mice (c) before and (d) after uninephrectomy and 28
days doxycycline administration. (b) Expansion of mesangial
matrix (arrow 1) was observed in almost half of the glomeruli;
podocyte detachment (arrow 2) and glomerular capillary
adherence to Bowman’s capsule (arrow 3) were observed in a very
few glomeruli at 14 days in PAN-treated rats. (d) Expansion of
mesangial matrix (arrow 1) and pseudocrescent (*) were observed
in a few glomeruli at 28 days in podocin/Vpr transgenic mice.
Tubular casts are marked with #.
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Distribution of ATF3 and WT-1 in different urine fractions
We selected urine samples with high levels of urinary ATF3
and WT-1 from a patient with AKI and a patient with FSGS,
respectively, to investigate the distribution of transcription
factors in various fractions of human urine. We standardized
gel loading by loading the same proportion of the original
urine volume for each fraction, except that unprocessed urine
was loaded on the gel at a maximum volume of the well. Both
urinary ATF3 (21 kDa) and WT-1 (52 kDa) were detected in
the urine exosome fraction (200,000 g pellet) but not in
unprocessed urine samples or urine sediments (17,000 g
pellet) (Figure 8a and b). These studies demonstrate that
transcription factors are mostly present in the exosome
fraction of human urine.
DISCUSSION
Transcription factors can be activated by physiological,
pathological, and therapeutic stimuli and orchestrate key
steps in renal development and in the initiation, persistence,
and repair of many kidney diseases. TFs are upregulated very
early in response to renal injury and thus could theoretically
serve as early detection markers. Studies from the mid-1990s
identified that renal c-myc increased over twofold at 7 days
after cisplatin injection in rats, and the renal c-fos and v-jun
increased after ischemia and reperfusion.27,28,41 More recent
microarray studies have identified many TFs that are drama-
tically upregulated in kidney tissue after exposure to
nephrotoxins or ischemia.27–29 Several groups have found
large increases in mRNA for ATF3, c-fos, c-jun, egr-1, and
gdf15; in addition, we found early and large increases in
crem, btg2, copeb, and tgif transcription factors. Whereas
changes in mRNA do not consistently predict changes in
protein levels for many genes,35 early-response TFs are
usually transcriptionally regulated, therefore mRNA fre-
quently predicts protein levels, at least acutely. The early
response and large magnitude of change after renal injury are
good characteristics for an ideal biomarker.2 However, TFs
are expressed at low levels intracellularly and hard to detect
outside of cells, which are poor characteristics for blood and
urinary biomarkers. As exosomes could contain intracellular
proteins sampled during invagination of the MVB at the time
of exosome formation, we hypothesized that we could detect
TF in exosomes expelled into the urine.
Activating transcription factor 3 is a member of the ATF/
CREB family of basic leucine zipper-type transcription
factors that is induced by a variety of physiological stimuli
and pathological stress signals.42 Recent studies suggest
that it regulates Toll-like receptor-stimulated inflammatory
responses as part of a negative-feedback loop43 and may alter
cell fate—with effects on both apoptosis and cell survival—
depending on the context.44 In this study, we selected ATF3
as a representative TF to investigate in AKI because we
recently found that renal ATF3 mRNA increased 14-fold in
the early phase (2 and 8 h) of both I/R- and cisplatin-
induced AKI by microarray.29 More critically, we found that
Normal
a
c d e
b
Normal
CG—28 days
CG—28 daysCG—14 days
Figure 6 | Immunofluorescence staining of WT-1 in kidneys
from podocin/Vpr transgenic mice. (a) WT-1-positive cells were
detected on the peripheral layer of glomerular capillaries from
normal mice but not in tubular cells and (b) significantly
decreased after uninephrectomy and 28 days doxycycline
administration. Lower panel: typical single glomerulus staining
of WT-1 from (c) normal mice, (d) 14 days, and (e) 28 days
of doxycycline in podocin/Vpr transgenic mice. Original
magnification is  200 for (a and b) and  630 for (c–e).
WT-1
WT-1
Normal
Normal
FSGS
FSGS
Female
Male
6.1 8.4 10.9 15.0 g/day proteinuria
g/day proteinuria2.2 2.8 4.0 6.4 8.4 20
Figure 7 | Urinary exosomal WT-1 in patients with FSGS.
Comparison of WT-1 in the exosomal fraction from spot urine
samples between healthy volunteers and patients with FSGS.
1 2 31 2 3
ATF3 21 kDa
52 kDaWT1
Figure 8 | The distribution of ATF3 and WT-1 in different urine
fractions. Urine samples obtained from (a) one patient with
AKI and (b) one patient with FSGS. Lane 1: whole urine; lane 2:
urine exosome fraction (200,000 g pellet); lane 3: urinary
sediment (17,000 g pellet).
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renal ATF3 protein was transiently increased at 8 h and
decreased to an undetectable level at 24 h in I/R AKI rats;29
similar to the findings reported by Yin et al.36 We, and
presumably others, did not pursue this otherwise logical hit
because we expected that ATF3 could not be detected outside
of cells. However, urinary exosomal ATF3 was detected as
early as 0–2 h after ischemia and reperfusion, peaked at 2–8 h,
which is before the maximum severity of renal tubular injury,
and was slightly decreased at 24 h in AKI rats (Figure 1a).
Urinary ATF3 was only detected in the exosomal fraction of
urine and was not detected in unfractionated urine,
presumably because of its low concentration.
Urinary exosomal ATF3 paralleled the initial rapid
increase in renal ATF3 expression but persisted even in the
face of declining tissue levels at the maximum of renal
tubular damage. We detected an unexpected biphasic pattern
in cisplatin-induced AKI (Figure 1b): urinary exosomal ATF3
was elevated on day 1, peaked at day 2, decreased to almost
undetectable levels at day 3, and then increased again at day 5
(Figure 1b) when renal tubule damage was the most severe.14
In addition, urinary ATF3 was also detected in four patients
with AKI; it decreased in one patient as the AKI became more
severe, and decreased in a second patient during the recovery
phase. The discrepancy between urinary exosomal and renal
tissue levels seen at 24 h after ischemia, and 3 days after
cisplatin, were unexpected. Although we cannot rule out
technical artifacts, such as sensitivity of detection or
differential release of exosomes during the 17,000 g centrifu-
gation, a biological explanation is more likely.
Because ATF3 can be an activator of transcription as a
heterodimer or a repressor in the homodimeric form,42 the
function of ATF3 should not be expected to be simple or
uniform. The unanticipated biphasic urinary exosomal ATF3
levels after cisplatin might reflect asynchronous waves of
injury and/or response to injury. Miyaji et al.45 demonstrated
that p53 peaked rapidly at day 1 after cisplatin injection and
returned to almost baseline at day 3; on the other hand, p21
started to increase at day 3 and gradually reached peak levels
at day 9. Recently, Yoshida et al.46 showed that ATF3
transfection protects mice against ischemia–reperfusion
injury resulting in suppression of p53 and induction of
p21, which is consistent with divergent functions of ATF3.
The biphasic ATF3 response may represent separate events in
different cell populations, as has been shown for heme
oxygenase 1 in nephrotoxic AKI.29 As useful as ATF3 may be
as an early biomarker, an additional biomarker, in conjunc-
tion with ATF3, would be needed to determine the severity of
injury, classification of injury type, or the timing of the
insult, and so on.
Transcription factors are also involved in developmental
programming of cells; during injury, cells can revert to a
dedifferentiated phenotype and often follow developmental
pathways during repair. Podocytes are highly differentiated
epithelial cells that contribute to the size- and charge-
selective glomerular filtration barrier. WT-1 is a zinc-finger
TF that is required for podocyte maturation, but remains
highly expressed into adulthood.33 Dominant WT-1 muta-
tions in the genes cause Wilms’ tumor and several podocyte
diseases, such as Denys–Drash syndrome, Frasier syndrome,
and isolated diffuse mesangial sclerosis.47 WT-1 is often used
as a molecular marker for differentiated podocytes and is
downregulated in a variety of glomerular diseases with
podocyte injury,34 including animal models of FSGS.39,48
Podocytes are injured, then lost in many primary and
secondary glomerular diseases, including FSGS, membranous
nephropathy, membranoproliferative glomerulonephritis,
amyloid nephropathy, and diabetic nephropathy.49 Podocyte
injury is currently verified by electron microscopic examina-
tion of renal biopsies. Noninvasive methods to quantify
podocyte damage are emerging, such as detection of
podocyturia,50,51 WT-1 mRNA,21 and podocyte-associated
proteins (podocalyxin) in the urinary sediment.22 However,
urinary podocytes are difficult to quantitate for technical
reasons,52 and WT-1 mRNA and podocalyxin are too variable
to differentiate disease from normal.21,53,54
We selected two established podocyte injury models
(puromycin-treated rats for FSGS and doxycycline-treated
podocin/Vpr mice for collapsing glomerulopathy) to exam-
ine WT-1, a transcription factor associated with podocytes.
Urinary exosomal WT-1 was detected earlier than proteinuria
and much earlier than glomerular histological damage in
FSGS animals (Figures 4 and 5). Urinary exosomal WT-1 was
detected in patients with FSGS, but not in age-matched
controls. As with ATF3, WT-1 was only detected in urinary
exosomes, and could not be detected in whole urine. That
urinary exosomal WT-1 increased in both models while tissue
levels of WT-1 were decreasing, either reported pre-
viously39,48 or evaluated by semi-qualitative immunofluores-
cence (Figure 5), suggests that exosomes are shed from
injured podocytes. It is not known whether the release
(shedding) occurs from the more normal podyctes (higher
levels of WT-1), perhaps accounting for the decreased tissue
levels, or from already dedifferentiated podocytes attached to
the glomerular basement membrane (GBM); or if podocytes
are shed first, then the exosomes are excreted from shed
podocytes. Nevertheless, these findings suggest that urinary
exosomal WT-1 may be a useful biomarker to detect
podocyte injury.
Transcription factors are involved in many common
pathways of kidney diseases. For example, YAP1p, AP-1,
and HSF1 are upregulated in response to oxidative stress;
NF-kB is a master switch for inflammatory responses; and
hypoxia-inducible factor (HIF-1 alpha) is a critical mediator
of cellular adaptation to hypoxia in acute ischemia kidney
injury, renal fibrosis, and renal cancer.55 TFs as reporters for
the pathophysiological mechanisms of renal disease is an
emerging concept. In urine sediments, the amount of mRNA
for FoxP3, a transcription factor related to the control of
immune response, has been reported to predict the outcome
of acute graft rejection after kidney transplantation.56 Nelson
et al.57 used a transgenic approach that introduced a hypoxia-
response element-linked b-hCG reporter to monitor tumor
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hypoxia. Chan et al.58 found that patients with active lupus
nephritis have increased T-bet mRNA and depressed GATA-3
mRNA, the principal transcription factors for differentiation
of type-1 and type-2 helper T lymphocytes, in the urine
sediments and kidney tissue; they also found that urinary
T-bet mRNA can track the effect of immunosuppressive
therapy.59 Although these studies measured urinary TF
mRNA, they suggest that urinary TFs are very promising
for early detection, classification, and monitoring treatment
of renal diseases.
We demonstrate here that the unique properties of exosomes
make it possible to measure protein levels of transcription
factors as a direct indicator of the status of cellular decision-
making processes. A combination of transcription factors may
be needed to maximize their potential as urinary biomarkers.
These results are encouraging, but there is much to be
developed before exosomal transcription factors can fulfill their
potential as biomarkers for clinical use. In addition to carefully
designed and adequately powered validation studies, the
current methods of ultracentrifugation and western blotting
must be streamlined. To simplify the exosome isolation
procedure, we demonstrated that a nanomembrane concen-
trator can be used in place of ultracentrifugation, making
urinary exosome analysis feasible in a clinical lab.54
CONCLUSION
We found that the transcription factors ATF3 and WT-1 are
concentrated in urinary exosomes to sufficiently high levels to
allow measurement of TFs in urinary exosomes, despite an
inability to detect TFs in whole urine. Urinary ATF3 might be
a novel renal tubular cell injury biomarker for detecting AKI,
whereas urinary WT-1 might be a useful biomarker to detect
podocyte injury in chronic kidney diseases. Both biomarker
candidates require further validation in larger sample sets.
Thus, transcription factors represent a new class of urinary
biomarkers for renal disease that may offer insight into critical
cellular regulatory pathways without the need for renal biopsy.
MATERIALS AND METHODS
Animals and urine collections
Male Sprague–Dawley rats were purchased from Harlan (Indiana-
polis, IN, USA). All animals had free access to water and standard
food and were treated in accordance with the National Institutes of
Health guidelines for care and use of research animals.
Podocin/rtTA transgenic mice were cross-bred with tetO/Vpr
transgenic mice to produce podocin/Vpr mice. During administration
of doxycycline, mice express Vpr selectively in podocytes and induce
glomerular damage similar to human HIV-associated FSGS.39
Urine samples from animals were collected using protease
inhibitors in metabolic cages, centrifuged at 1000 g for 10 min to
remove debris, and stored at 801C until the isolation of exosome-
associated proteins as described previously14,26
AKI models
Cisplatin-induced AKI (n¼ 28): rats (250–280 g; 8 weeks of age)
were given a single intravenous injection of cisplatin (6 mg per kg
body weight) (Sigma-Aldrich, St Louis, MO, USA). Blood samples
were collected from the tail vein in eight rats under isoflurane
anesthesia before (day 0) and at 1, 2, 3, and 5 days after cisplatin
injection. Corresponding 8 h urine samples were collected on ice at
the same time points from the same rats for the analysis of urinary
transcription factors. Kidney tissues were harvested after kidney
perfusion of abdominal aorta by precooled 1 phosphate-buffered
saline from four rats at each time point.
Ischemia/reperfusion-induced AKI (n¼ 4): rats (180–210 g;
7 weeks) were subjected to 35 min bilateral ischemia and reperfusion
(I/R) as described previously.11 Urine samples were collected before
(24 to 16 h) I/R, and at 0–2, 2–8, and 8–24 h after I/R. The rats
were killed at 8 or 24 h after I/R for the collection of blood samples
and kidney tissues.
Volume depletion (n¼ 4): Rats (380–400 g; 14 weeks) were fed a
low salt diet (0.03%) (Diet Test Inc. Philadelphia, PA, USA) 18 h
before intraperitoneal injection of furosemide as previously
described.11 We collected 6 h-urine samples at 24 to 18 h before
and 24–30 h after volume depletion. Rats were killed at 33 h after
furosemide injection for blood collection.
Podocyte injury models
PAN-induced FSGS rats (n¼ 4): rats (290–315 g; 9 weeks) were given
an intravenous injection (60 mg/kg) of PAN (Biomol Research
Laboratories, Plymouth Meeting, PA, USA). Twenty-four-hour
urine samples were collected on ice before PAN and at days 1, 2,
3, 4, 5, 6, 7, and 14 after PAN injection for examination of
proteinuria and urinary transcription factors. The rats were killed at
14 days after PAN injection for collection of blood samples and
kidney tissues.
Combination of uninephrectomy and doxycycline-induced CG
mice (n¼ 5): podocin/Vpr mice (25–35 g, 12 weeks) were subjected
to uninephrectomy 1 week before the administration of doxycycline
(Sigma-Aldrich, St Louis, MO, USA). Doxycycline was given in
drinking water (2 mg/ml) for 28 days to induce Vpr expression
in podocytes.39 Twenty-four-hour urine samples were collected in
metabolic cages before uninephrectomy and days 7, 14, 21, and 28
after beginning doxycycline administration for urinary exosomal
WT-1 examination. The mice were killed at day 14 (n¼ 2) and day
28 (n¼ 3) for collection of blood and kidney tissue.
Patients and urine collections
All samples were collected under IRB-approved protocols at the
National Institutes of Health Clinical Center or George Washington
University, and all patients gave informed consent.
Acute kidney injury patients: we collected spot human urine
samples from eight healthy volunteers and four ICU patients with
AKI as defined by the Acute Kidney Injury Network.60,61 In two AKI
patients, we collected two urine samples: an early time point and
near the peak SCr in one patient, and peak and recovery time points
in another AKI patient.
Chronic kidney disease patients: we collected spot urine samples
from 10 FSGS patients, 8 age- and gender-matched healthy controls,
and 4 patients with lupus nephritis or diabetic nephropathy.
Protease inhibitors were added into all spot urine samples. Urine
samples were subjected to a low spin (1000 g, 10 min) to remove
cellular debris and then stored at 801C until the isolation of
exosome-associated proteins as described previously.26 Exosomal
protein was normalized with urinary creatinine.14,26
Examination of blood chemistry and proteinuria
Serum creatinine for rats was measured by picric acid-based colori-
metric autoanalyzer (Astra 8 autoanalyzer; Beckman Instruments,
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Fullerton, CA, USA); blood urea nitrogen, albumin and total protein
were measured by an autoanalyzer (Hitachi 917, Boehringer
Mannheim, Indianapolis, IN, USA). SCr for podocin/Vpr mice was
measured by high-pressure liquid chromatography analysis.62 The
proteinuria in PAN-treated rats was semiquantitatively determined by
urine test Chemstrips (Roche, Indianapolis, IN, USA) and albumi-
nuria in podocin/Vpr mice was measured by albumin enzyme-linked
immunosorbent assay (Exocell, Philadelphia, PA, USA).
Isolation of urinary exosomes and fractionation of urine
Urine samples were extensively vortexed immediately after thawing.
Urinary exosome-associated proteins were isolated by differential
centrifugation (17,000 g for 15 min to remove urinary sediment then
200,000 g for 1 h) as described previously.14,23,26 Exosomes were
isolated from timed urine collections (animal studies) or 10–16 ml of
spot urine samples (human studies). To determine whether
transcription factors could be enriched in urine fractions, urine
samples from one AKI patient and one FSGS patient were
unfractionated (whole urine) or separated into urine sediment
(17,000 g pellet) and exosome (200,000 g pellet) fractions.
Western blot analysis of ATF3 and WT-1
Gel loading of urinary exosome-associated proteins was normalized
by collection time for animal studies, by urine creatinine for human
studies, and with the same proportion of original urine volume for
different fractions from the same patient (Figure 8) as described
previously.14 Protein samples were separated by 1D sodium dodecyl
sulfate–polyacrylamide gel electrophoresis electrophoresis and then
gels were transferred to polyvinylidene difluoride membranes. After
blocking with 5% milk (1 h), membranes were probed overnight
at 41C with rabbit polyclonal antibody to ATF3 (1:200) (Santa Cruz
Biotechnology, CA, USA) or WT-1 (1:200) (Santa Cruz Biotechno-
logy). Blots were then incubated with peroxidase-conjugated,
affinity-purified donkey anti-rabbit IgG (1:100,000) (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA) for 90 min
at room temperature (RT). The antibody–antigen reactions were
visualized by using enhanced chemiluminescence (ECL) plus western
blotting detection system (GE Healthcare, Piscataway, NJ, USA) and
BioMax XAR light-sensitive film (Kodak, Rochester, NY, USA).
Examination of histology and immunohistochemistry
Under anesthesia, half of the left kidney was removed and
immediately fixed in 10% neutral buffered formalin solution for
paraffin embedding, and the other half was embedded in OCT
medium (Sakura, Torrance, CA, USA).
The paraffin-embedded kidney blocks were cut at 4 mm
thickness, deparaffinized, rehydrated, and then stained with periodic
acid Schiff reagent for histological examination. For immunohis-
tochemistry, sections were incubated with 3% H2O2 to consume
endogenous peroxidase, pre-incubated with 10% normal donkey
serum to block nonspecific binding, and incubated with polyclonal
rabbit anti-ATF3 (1:100) (Santa Cruz) overnight at 41C. The slides
were followed by incubation with biotin-conjugated donkey anti-
rabbit IgG (1:1000) (Jackson ImmunoResearch) for 30 min at RT,
and then reacted with streptavidin-conjugated peroxidase (Dako
Corp., Carpinteria, CA, USA) for 30 min at RT. The reaction
products were visualized using a DAB kit (Vector Laboratories,
Burlingame, CA, USA).
The frozen kidney tissues from podocin/Vpr transgenic mice
were used for immunofluorescent staining of WT-1. Frozen kidneys
were sectioned (5mm) and slides were fixed in 2% paraformaldehyde
for 10 min and then permeabilized in 0.3% Triton X-100 in
phosphate buffered saline for 5 min. Nonspecific binding was
blocked by using blocking buffer for 1 h at RT. The slides were
incubated with anti-WT-1 antibody (Santa Cruz) at 41C overnight,
followed by incubation with Alexa-488-conjugated secondary
antibodies (Invitrogen, Carlsbad, CA, USA) at RT for 1 h. After
several washes with phosphate-buffered saline, slides were em-
bedded in mounting reagent (Invitrogen). Images were captured
using a fluorescent microscope (Leica Microsystems, Wetzlar
GmbH, Germany). The positive staining of ATF3 was inhibited
more than 90% by pre-incubating primary antibody with ATF3
peptide at day 3 after cisplatin injection (ATF3-positive nuclei 2±1
cells vs 25±5 cells/high power field) (n¼ 3/group).
Statistical analysis
All data are expressed as mean±s.e.m. Differences between groups
were analyzed for statistical significance by t-test or analysis of
variance. A P-value o0.05 was accepted as statistically significant.
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